PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33961984-9	2021	Niclosamide (5 and 10 mg/kg) also significantly reduced NOTCH pathway (Jagged1, NOTCH2, NOTCH3, HES1, SOX9), Wnt pathway (Wnt5B, and Wnt10A), and fibrosis (transforming growth factor-beta1 (TGF-beta1), alpha smooth muscle actin (alpha-SMA) and collagen deposition with more prominent effect of the higher dose 10 mg/kg.	Niclosamide	0-11	transforming growth factor, beta 1	Rattus norvegicus	156-188	
33961984-9	2021	Niclosamide (5 and 10 mg/kg) also significantly reduced NOTCH pathway (Jagged1, NOTCH2, NOTCH3, HES1, SOX9), Wnt pathway (Wnt5B, and Wnt10A), and fibrosis (transforming growth factor-beta1 (TGF-beta1), alpha smooth muscle actin (alpha-SMA) and collagen deposition with more prominent effect of the higher dose 10 mg/kg.	Niclosamide	0-11	transforming growth factor, beta 1	Rattus norvegicus	190-199	
32882667-13	2020	RESULTS: The group of niclosamide-and-CCl4-treated rats showed a significant decrease in total bilirubin, ALT and AST, beta-catenin, l-hydroxyproline, l-glutaminase activity, and gene expression of TGF-beta1 and Dvl2.	Niclosamide	22-33	transforming growth factor, beta 1	Rattus norvegicus	198-207	
26912210-7	2016	Blocking Wnt signaling using a Frizzled receptor inhibitor (Niclosamide) abolished TGF-beta/Smad3-induced beta-catenin stabilization.	Niclosamide	60-71	transforming growth factor, beta 1	Rattus norvegicus	83-91